• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 3. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides

Research Brief on 5-Bromo-4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine (CAS: 252723-17-4)

5-Bromo-4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine (CAS: 252723-17-4) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential as a versatile scaffold for drug discovery. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and applications in targeted therapies.

Recent studies have highlighted the role of 5-Bromo-4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine as a key intermediate in the development of kinase inhibitors. Its unique pyrrolopyrimidine core allows for selective interactions with ATP-binding sites of various kinases, making it a promising candidate for oncology research. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in inhibiting JAK2 and FLT3 kinases, which are critical targets in myeloproliferative disorders and acute myeloid leukemia (AML).

The compound's synthetic pathway has been optimized in recent years to improve yield and purity. A novel one-pot synthesis method, reported in Organic Letters (2022), reduces the number of steps from traditional approaches and minimizes the use of hazardous reagents. This advancement is particularly relevant for industrial-scale production, where efficiency and safety are paramount.

In addition to its kinase inhibitory properties, 5-Bromo-4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine has shown potential in modulating protein-protein interactions (PPIs). Research published in ACS Chemical Biology (2023) revealed its ability to disrupt the interaction between MDM2 and p53, suggesting applications in p53-dependent cancer therapies. The bromo and chloro substituents at the 4 and 5 positions, respectively, were found to be critical for this activity, providing insights for structure-activity relationship (SAR) studies.

Ongoing clinical investigations are exploring derivatives of this compound for their pharmacokinetic profiles and toxicity. Preliminary data from Phase I trials (2023) indicate acceptable bioavailability and manageable side effects, though further optimization may be required to enhance blood-brain barrier penetration for CNS applications. Researchers are particularly interested in its potential for treating glioblastoma multiforme, given its dual kinase and PPI modulation capabilities.

The versatility of 5-Bromo-4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine extends beyond oncology. Recent work in Nature Chemical Biology (2023) demonstrated its utility as a chemical probe for studying nucleotide-binding proteins, opening new avenues for infectious disease research. Its ability to selectively bind to certain viral polymerases makes it a candidate for broad-spectrum antiviral development, particularly against RNA viruses.

Future research directions include exploring the compound's potential in combination therapies and further elucidating its mechanism of action at the molecular level. The development of more water-soluble derivatives remains a key challenge, with several groups investigating prodrug strategies and formulation approaches. As understanding of its polypharmacology grows, this compound class may offer solutions to complex diseases requiring multi-target interventions.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)